O	0	4	High
O	5	9	Ki67
O	10	18	predicts
O	19	31	unfavourable
O	32	40	outcomes
O	41	43	in
O	44	49	early
O	50	56	breast
O	57	63	cancer
O	64	72	patients
O	73	77	with
O	78	79	a
O	80	90	clinically
O	91	96	clear
O	97	103	axilla
O	104	107	who
O	108	110	do
O	111	114	not
O	115	122	receive
B-intervention	123	131	axillary
I-intervention	132	142	dissection
O	143	145	or
B-control	146	154	axillary
I-control	155	167	radiotherapy
O	167	168	.

O	169	177	Axillary
O	178	188	dissection
O	189	191	is
O	192	204	increasingly
O	205	212	forgone
O	213	215	in
O	216	221	early
O	222	228	breast
O	229	235	cancer
O	236	244	patients
O	245	249	with
O	250	251	a
O	252	262	clinically
O	263	271	negative
O	272	278	axilla
O	278	279	.

O	280	283	The
O	284	289	GRISO
O	290	293	053
O	294	304	randomised
O	305	310	trial
O	311	320	recruited
B-total-participants	321	324	435
O	325	333	patients
O	334	336	of
O	337	340	age
B-age	341	345	over
I-age	346	348	45
I-age	349	354	years
O	354	355	,
B-eligibility	356	362	tumour
I-eligibility	363	364	≤
I-eligibility	364	365	1
I-eligibility	365	366	.
I-eligibility	366	367	4
I-eligibility	368	370	cm
I-eligibility	371	374	and
I-eligibility	375	385	clinically
I-eligibility	386	394	negative
I-eligibility	395	401	axilla
O	401	402	,
O	403	405	to
O	406	412	assess
O	413	416	the
O	417	427	importance
O	428	430	of
O	431	439	axillary
O	440	452	radiotherapy
O	453	459	versus
O	460	462	no
O	463	471	axillary
O	472	484	radiotherapy
O	485	487	in
O	488	496	patients
O	497	500	not
O	501	506	given
O	507	515	axillary
O	516	526	dissection
O	526	527	.

O	528	530	In
O	531	534	the
O	535	542	present
O	543	548	study
O	549	551	on
O	552	553	a
O	554	562	subgroup
O	563	568	GRISO
O	569	574	cases
O	575	578	our
O	579	582	aim
O	583	586	was
O	587	589	to
O	590	596	assess
O	597	600	the
O	601	611	prognostic
O	612	622	importance
O	623	625	of
O	626	632	tumour
O	633	643	biological
O	644	651	factors
O	652	657	after
O	658	662	more
O	663	667	than
O	668	670	10
O	671	676	years
O	677	679	of
O	680	686	follow
O	686	687	-
O	687	689	up
O	689	690	.

O	691	693	We
O	694	709	retrospectively
O	710	718	assessed
O	719	729	biological
O	730	737	factors
O	738	740	in
O	741	742	a
O	743	751	subgroup
O	752	754	of
O	755	758	285
O	759	764	GRISO
O	765	770	cases
O	771	772	(
B-control-participants	772	775	145
O	776	781	given
O	782	790	axillary
O	791	803	radiotherapy
O	803	804	;
B-intervention-participants	805	808	140
O	809	812	not
O	813	818	given
O	819	827	axillary
O	828	840	radiotherapy
O	840	841	)
O	842	846	with
O	847	855	complete
O	856	864	biologic
O	864	865	,
O	866	877	therapeutic
O	878	881	and
O	882	888	follow
O	888	889	-
O	889	891	up
O	892	903	information
O	903	904	,
O	905	910	using
O	911	924	multivariable
O	925	928	Cox
O	929	941	proportional
O	942	949	hazards
O	950	960	regression
O	961	970	modelling
O	970	971	.

O	972	976	Only
B-outcome	977	979	10
I-outcome	979	980	-
I-outcome	980	984	year
I-outcome	985	995	cumulative
I-outcome	996	1005	incidence
I-outcome	1006	1008	of
I-outcome	1009	1016	distant
I-outcome	1017	1027	metastasis
O	1028	1031	was
O	1032	1037	lower
O	1038	1040	in
O	1041	1044	the
O	1045	1053	axillary
O	1054	1066	radiotherapy
O	1067	1068	(
B-cv-bin-percent	1068	1069	1
I-cv-bin-percent	1069	1070	%
O	1070	1071	)
O	1072	1076	than
O	1077	1079	no
O	1080	1088	axillary
O	1089	1101	radiotherapy
O	1102	1105	arm
O	1106	1107	(
B-iv-bin-percent	1107	1108	7
I-iv-bin-percent	1108	1109	%
O	1109	1110	)
O	1111	1112	(
O	1112	1113	p
O	1113	1114	=
O	1114	1115	0
O	1115	1116	.
O	1116	1119	037
O	1119	1120	)
O	1120	1121	.

O	1122	1134	Irrespective
O	1135	1137	of
O	1138	1143	study
O	1144	1147	arm
O	1147	1148	,
O	1149	1156	hormone
O	1157	1165	receptor
O	1166	1176	positivity
O	1177	1180	had
O	1181	1194	significantly
O	1195	1205	favourable
O	1206	1213	effects
O	1214	1216	on
B-outcome	1217	1219	10
I-outcome	1219	1220	-
I-outcome	1220	1224	year
I-outcome	1225	1232	disease
I-outcome	1232	1233	-
I-outcome	1233	1237	free
I-outcome	1238	1246	survival
I-outcome	1247	1248	(
I-outcome	1248	1251	DFS
I-outcome	1251	1252	)
O	1253	1256	and
B-outcome	1257	1264	overall
I-outcome	1265	1273	survival
O	1273	1274	.
O	1275	1280	human
O	1281	1290	epidermal
O	1291	1297	growth
O	1298	1304	factor
O	1305	1313	receptor
O	1314	1315	2
O	1316	1317	(
O	1317	1321	HER2
O	1321	1322	)
O	1322	1323	-
O	1323	1331	positive
O	1332	1335	and
O	1336	1342	triple
O	1342	1343	-
O	1343	1351	negative
O	1352	1360	subtypes
O	1361	1365	were
O	1366	1376	associated
O	1377	1381	with
O	1382	1387	lower
B-outcome	1388	1390	10
I-outcome	1390	1391	-
I-outcome	1391	1395	year
I-outcome	1396	1399	DFS
O	1400	1401	(
O	1401	1403	60
O	1403	1404	%
O	1405	1408	and
O	1409	1411	76
O	1411	1412	%
O	1412	1413	,
O	1414	1426	respectively
O	1426	1427	)
O	1428	1432	than
O	1433	1440	luminal
O	1441	1442	A
O	1443	1444	(
O	1444	1446	96
O	1446	1447	%
O	1447	1448	)
O	1449	1452	and
O	1453	1454	B
O	1455	1456	(
O	1456	1458	91
O	1458	1459	%
O	1459	1460	)
O	1461	1462	(
O	1462	1463	p
O	1463	1464	=
O	1464	1465	0
O	1465	1466	.
O	1466	1469	001
O	1469	1470	)
O	1470	1471	.

B-outcome	1472	1475	Ten
I-outcome	1475	1476	-
I-outcome	1476	1480	year
I-outcome	1481	1484	DFS
O	1485	1488	for
O	1489	1493	high
O	1494	1495	(
O	1495	1496	≥
O	1496	1498	14
O	1498	1499	%
O	1499	1500	)
O	1501	1505	Ki67
O	1506	1513	cancers
O	1514	1517	was
O	1518	1523	lower
O	1524	1528	than
O	1529	1532	for
O	1533	1536	low
O	1537	1541	Ki67
O	1542	1549	cancers
O	1550	1551	(
O	1551	1552	p
O	1552	1553	=
O	1553	1554	0
O	1554	1555	.
O	1555	1558	027
O	1558	1559	)
O	1559	1560	;
O	1561	1568	however
O	1568	1569	,
O	1570	1574	this
O	1575	1581	effect
O	1582	1585	was
O	1586	1592	mainly
O	1593	1601	confined
O	1602	1604	to
O	1605	1608	the
O	1609	1611	no
O	1612	1620	axillary
O	1621	1633	radiotherapy
O	1634	1637	arm
O	1637	1638	.

O	1639	1642	For
O	1643	1651	patients
O	1652	1656	with
O	1657	1667	clinically
O	1668	1672	node
O	1672	1673	-
O	1673	1681	negative
O	1682	1687	small
O	1688	1694	breast
O	1695	1701	cancer
O	1702	1705	not
O	1706	1711	given
O	1712	1720	axillary
O	1721	1731	dissection
O	1731	1732	,
O	1733	1735	10
O	1735	1736	-
O	1736	1740	year
O	1741	1744	DFS
O	1745	1747	is
O	1748	1756	worsened
O	1757	1759	by
O	1760	1764	HER2
O	1765	1775	positivity
O	1775	1776	,
O	1777	1783	triple
O	1783	1784	-
O	1784	1792	negative
O	1793	1802	phenotype
O	1803	1806	and
O	1807	1811	high
O	1812	1816	Ki67
O	1816	1817	.

O	1818	1826	Axillary
O	1827	1839	radiotherapy
O	1840	1851	counteracts
O	1852	1855	the
O	1856	1864	negative
O	1865	1875	prognostic
O	1876	1882	effect
O	1883	1885	of
O	1886	1890	high
O	1891	1895	Ki67
O	1896	1898	in
O	1899	1907	patients
O	1908	1911	not
O	1912	1921	receiving
O	1922	1930	axillary
O	1931	1941	dissection
O	1941	1942	.
